|
![]() |
|
|
Cefixime
drug data and news
Cefixime drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Cefixime | ||
| Brand Names/Synonyms | CFIX; Cefixim; Cefixima [Spanish]; Cefixime; Cefixime Anhydrous; Cefixime [Usan:Ban:Inn:Jan]; Cefiximum [Latin]; Cefixoral; Cefspan; Cephoral; FK 027; Oroken; Suprax; Unixime | ||
| Indication | For the treatment of the following infections (UTI, respiratory, ENT) caused by; E.coli, P.mirabilis, H.influenzae (beta-lactamase positive and negative strains), M.catarrhalis, (most of which are beta-lactamase positive), S. pyogenes, S.pneumoniae, N.gon | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Cefixime, an antibiotic, a third-generation cephalosporin like ceftriaxone and cefotaxime, is used in the treatment of otitis media, and respiratory tract and urinary tract infections. The antibacterial effect results from inhibition of mucopeptide synthesis in the bacterial cell wall | ||
| Mechanism Of Action | Like all beta-lactam antibiotics, cefixime binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefixime interferes with an autolysin inhibitor. | ||
| Cefixime News (When available) |
Steep fall in prices of medicines Feb 19, 2006 An open letter to the pharmaceutical industry Jan 29, 2006 Prescribing medicine in Ramzan Oct 20, 2005 Lupin gets USFDA nod Aug 18, 2005 Treating Partners Immediately Reduces Recurrence of STDs Jul 31, 2005 US tonic helps Lupin dream big Jul 8, 2005 US tonic helps Lupin dream big Jul 8, 2005 Lupin in marketing pact with US firms May 29, 2005 Lupin strikes outlicencing deal with Cornerstone May 13, 2005 Gay men continue to see gonorrhoea rises May 5, 2005 Lupin looks to beef up US presence, eyes $100m buy Mar 3, 2005 Lupin's unsexy, but great, success story! Mar 3, 2005 Immediate Access To Antibiotics Stems Spread Of Sexually ... Mar 4, 2005 | ||
| Dosage Forms | Oral Suspension; Tablet; POWDER FOR SOLUTION; POWDER FOR SUSPENSION | ||
| Drug_Category | Anti-bacterial Agents; Cephalosporins; ATC:J01DD08 | ||
| Absorption | Orally 40-50% | ||
| Interactions |
-->Interactions for Cefixime: Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly. Drug monitoring may be of assistance in detecting alterations in carbamazepine plasma concentrations. Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly. Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide. The administration of SUPRAX may result in a false-positive reaction for glucose in the urine using ClinitestÒ**, Benedictís solution, or Fehlingís solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix®** or Tes-TapeÒ**) be used. A false-positive direct Coombs test has been reported during treatment with other cephalosporin antibiotics; therefore, it should be recognized that a positive Coombs test may be due to the drug. | ||
| Toxicity | CNS: Headache, dizziness, lethargy, paresthesias. GI: Nausea, vomiting, diarrhea, anorexia, abdominal pain, flatulence, pseudomembranous colitis, liver toxicity. Hematologic: Bone marrow depression. GU: Nephrotoxicity. Hypersensitivity: Ranging from rash to fever to anaphylaxis, serum sickness reaction. Other: Superinfections, disulfiram-like reaction with alcohol | ||
| Organisms Affected | Enteric bacteria and other eubacteria | ||
| Chemical IUPAC Name | 8-[2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino-4-ethenyl-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-carboxylic acid | ||
| Chemical Formula | C16H15N5O7S2 | ||
| Molecular Weight | 453.452 g/mol | ||
| Smiles String | C=CC1=C(N2C(C(C2=O)NC(=O)C(=NOCC(=O)O)C3=CSC(=N3)N)SC1)C(=O)O | ||
| Melting Point | 218-225 °C | ||
| Water Solubility | 55.11mg/L | ||
| State | powder | ||
| LogP/Hphobicity | -0.559 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | liver 16.2% | ||
| Half Life | 3-4 hours | ||
| Protein Binding [%] | 65% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Cefixime.html http://www.rxlist.com/cgi/generic/cefixime.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00583 | ||
| CAS Registry Number | 79350-37-1 | ||
| KEGG Compound ID | C06881 | ||
| PubChem ID | SID:9098 | ||
| PharmGKB ID | PA448844 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2195992 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |